Skip to Content

The first-in-class antibody talquetamab show a high clinical response rate in patients with relapsed and refractory multiple myeloma

Talquetamab is a first-in-class bispecific immunoglobulin G4 antibody that binds to CD3 and GPRC5D for activating T cells to attack multiple myeloma cells. The phase I study MonumentTAL-1 has shown high clinical response rate in patients with relapsed and refractory multiple myeloma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top